Prostate-specific antigen: A diagnostic marker and a tool for targeted delivery of drugs to prostate tumours

Expert Opinion on Therapeutic Patents

Volumn 12, Issue 7, 2002, Pages 1035-1046

  Frydman, Benjamin ^a   Basu, Hirak S ^a  

^a SLIL Biomedical Corp   (United States)

Author keywords

Bound PSA; Free PSA; Peptide conjugates; Prostate cancer; Prostate specific antigens; Prostate specific enhancer; Prostate specific membrane antigen; PSA enzymatic activity; Targeted delivery

Indexed keywords

7 AMINO METHYLCOUMARIN; ANTINEOPLASTIC AGENT; BETA LAPACHONE; COUMARIN DERIVATIVE; CYTOTOXIC AGENT; DOXORUBICIN; DRUG CARRIER; FIBRONECTIN; FLUOROURACIL; GLYCOPROTEIN; KALLIKREIN; KININ; KININOGEN; LAMININ; MONOCLONAL ANTIBODY; POLYAMINE DERIVATIVE; PRODRUG; PROSTATE SPECIFIC ANTIGEN; SCLEROPROTEIN; SERINE PROTEINASE; SL 11093; SL 11154; SL 11168; SL 11173; SL 11240; SOMATOMEDIN; SPERMINE; THAPSIGARGIN; TUMOR MARKER; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN DETECTION; ANTIGEN PURIFICATION; ANTINEOPLASTIC ACTIVITY; CANCER INHIBITION; CANCER MORTALITY; CANCER TRANSPLANTATION; CONTROLLED STUDY; DRUG ACTIVATION; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG METABOLISM; DRUG STRUCTURE; DRUG TARGETING; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME RELEASE; ENZYME STRUCTURE; ENZYME SUBSTRATE; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; NUDE MOUSE; PROGNOSIS; PROSTATE; PROSTATE TUMOR; PROTEIN DEGRADATION; RAT; REVIEW; SEMINAL PLASMA; TUMOR GROWTH; TUMOR VOLUME; UNITED STATES;

EID: 0036319043     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.12.7.1035     Document Type: Review

References (61)

1. Purification of a human prostate specific antigen
2. Quantitation of prostate-specific antigen in serum by a sensitive enzyme immunoassay
3. Prostate antigen: A new potential marker for prostatic cancer
4. Pre-treatment and post-treatment evaluation of prostatic adenocarcinoma for prostatic specific acid phosphatase and prostatic specific antigen by immunohistochemistry
5. Circulating prostate specific antigen-positive cells correlate with metastatic prostate cancer
6. Early detection of prostate cancer
7. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage Tlc) prostate cancer
8. Prognostic significance of positive surgical margins in radical prostatectomy specimens
9. Radical prostatectomy for adenocarcinoma of the prostate: The influence of preoperative and pathologic findings on biochemical disease-free outcome
10. Prostate-specific antigen is a new favorable prognostic indicator for women with breast cancer
11. Prostatic-specific antigen: An immunohistologic marker for prostatic neoplasms
12. Prostate antigen: A marker for human prostate epithelial cells
13. In situ hybridization of prostate-specific antigen mRNA in human prostate
14. Enzymatic activity of prostate-specific antigen and its reactions with extracellular serine proteinase inhibitors
15. A kallikrein-like serine protease in prostatic fluid cleaves the predominant seminal vesicle protein
16. Sentinal vesicle-secreted proteins and their reactions during gelation and liquefaction of human semen
17. Human seminal vesicle-specific antigen is a substrate for human prostate-specific antigen (or P-30)
18. Liquefaction of coagulated human semen
19. Human seminal vesicle-specific antigen during semen liquefaction
20. Prostate-specific antigen (PSA) is an insulin-like growth factor binding protein-3 protease found in seminal plasma
21. Serum prostate specific antigen completed to α1-antichymotrypsin as an indicator of prostate cancer
22. Prostate-specific antigen in serum occurs predominantly in complex with αI-antichymotrypsin
23. A complex between prostate-specific antigen and α1 antichymotrypsin I the major form of prostate-specific antigen in serum of patients with prostatic cancer: Assay of the complex improves clinical sensitivity for cancer
24. Analysis of the plasma elimination kinetics and conformational stabilities of native, proteinase complexed, and reactive site cleaved serpins: Comparison of α1 proteinase inhibitor, α1-antichymotrypsin, α2-antiplasmin, angiotensinogen, and ovalbuniin
25. Identification of a serpin-enzyme complex receptor on human hepatoma cells and human monocytes
26. Prostate specific antigen
27. Androgen-sensitive human prostate cancer cells, LNCAP, produce both N-terminally mature and truncated prostate-specific antigen isoforms
28. Characterization and processing of prostate-specific antigen (hK3) and human glandular kallikrein 2 (hK2) secreted by LNCAP cells
29. Different proportions of various prostate-specific antigen (PSA) and human kallikrein 2 (hK2) forms are present in noninduced and androgen induced LNCaP cells
30. Expression of pro form of prostate-specific antigen by mammalian cells and its conversion to mature, active form by human kallikrein 2
31. Characterization of the precursor of prostate-specific antigen
32. Activation of zymogen form of prostate-specific antigen by human glandular kallikrein 2
33. Molecular cloning of human prostate specific antigen CDNA
34. Characterization of the gene for prostate-specific antigen, a human glandular kallikrein
35. Characterization of the prostate-specific antigen gene: A novel human kallikrein like gene
36. Immunocytochemical localisation of prostate-specific antigen: Specificity and application to clinical practice
37. Expression, purification and characterization of deglycosylated human pro-prostate specific antigen
38. Production of recombinant PSA and hK2 and analysis of their immunologic cross-reactivity
39. Free and complexed prostate-specific antigen (PSA): In vitro stability, epitope map, and development of immunofluoremetric assays for specific and sensitive detection of free PSA and PSA-α1-antichymotrypsin complex
40. Antibody immunoglobulin G (IgG) against human prostatic specific antigen (PSA) as a carrier protein for chemotherapeutic drugs to human prostate tumors: Part 1. A double immunofluorescence analysis
41. An α-particle emitting antibody ([213Bi]J591) for radioimmunotherapy of prostate cancer
42. Generation of cytotoxic agents by targeted enzymes
43. Disposition of the prodrug 4-(bis (2-chloroethyl) amino) benzoyl-L-glutamic acid and its active parent drug in mice
44. Specific and efficient peptide substrates for assaying the proteolytic activity of prostate-specific antigen
45. Enzymatic activation of a doxorubicin-peptide prodrug by prostate-specific antigen
46. In vivo activity of a PSA-activated doxorubicin prodrug against PSA-producing human prostate cancer xenografts
47. A peptide-doxorubicin 'prodrug' activated by prostate-specific antigen selectively kills prostate tumor cells positive for prostate-specific antigen in vivo
48. Design, synthesis, and pharmacological evaluation of thapsigargin analogues for targeting apopotosis to prostatic cancer cells
49. Concentration of enzymatically active prostate-specific antigen (PSA) in the extracellular fluid of primary human prostate cancers and human prostate cancer xenograft models
50. Induction of DNA topoisomerase II-mediated DNA: Cleavage by β-lapachone and related naphthoquinones
51. Effects of 1,2-naphthoquinones on human tumor cell growth and lack of cross-resistance with other anticancer agents
52. Comparison of anti-prostate-specific membrane antigen antibodies and other immunomarkers in metastatic prostate carcinoma
53. Prostate-specific suicide gene therapy using the prostate-specific membrane antigen promoter and enhancer
54. Polyamines in mammalian biology and medicine
55. Polyamine-based chemotherapy of cancer
56. 12-bisethylspermine: Synthesis and growth inhibitory effects on human tumor cell lines
57. 14-bisethylhomospermine (BE-4-4-4): Synthesis and growth inhibitory effects on human prostate cancer cells
58. Cis-Unsaturated analogues of 3,8,13,18,23-pentaazapentacosane (BE-4-4-4-4): Synthesis and growth inhibitory effects on human prostate cancer cell lines
59. Solid-phase extraction and determination of dansyl derivatives of unconjugated and acetylated polyamines by reversed-phase liquid chromatography: Improved separation systems for polyamines in cerebrospinal fluid, urine, and tissue
60. A Guide to the polyamines
61. 14-diethylhomospermine